ICICI Securities believes the stronger growth trajectory and improving profitability justify Honasa's higher earnings estimates and valuation.
Set as Trusted Source
on Google Search
ICICI Securities believes the stronger growth trajectory and improving profitability justify Honasa's higher earnings estimates and valuation.
Akums Drugs, CDSL, Ceigall and Power Mech have received fresh brokerage commentary from ICICI Securities following their June-quarter earnings, with the brokerage taking sharply different views across the four stocks.
The brokerage flagged persistent weakness in advertising revenue and an earnings miss as key concerns, even as subscription revenue remained strong and ZEE5 delivered another profitable quarter.
Titan Company, Fortis Healthcare, Hindalco Industries, Blue Star and Ramco Cements are in focus following their Q1 FY27 earnings, with ICICI Securities taking a differentiated view across the five stocks.
Cera, GE Vernova T&D India, Power Grid, Power Finance are among the stocks in focus after Motilal Oswal reviewed their June-quarter performance, with the brokerage highlighting strong execution, healthy order visibility and long-term growth opportunities across building materials and power infrastructure.
Revenue surged 69% YoY, profit more than doubled and order inflows exceeded expectations, prompting ICICI Securities to upgrade the stock to 'Buy'
The report highlighted that Delhivery continues to gain market share across key segments while benefiting from increasing outsourcing by e-commerce companies and new customer acquisitions.
Cohance's lower utilisation at manufacturing plants, higher overheads and continued losses at NJ bio resulted in exceptionally weak margin, adds the brokerage.
Given that DAC approvals of Rs 52,000 crore, were at an all-time high in FY26, the brokerage expects the order awarding momentum to pick up in FY27/28, especially in aerospace, missiles, electronic warfare and drone defence-offence side.
DOMS Industries, Inox India and United Breweries, Orkla India are likely to remain in focus after ICICI Securities reviewed their June-quarter earnings, maintaining a constructive stance on all four stocks.
Among the three, Alembic Pharma delivered one of the strongest performances.
The brokerage believes the jewellery retailer's strong growth momentum, improving return ratios and rapid debt reduction outweigh near-term margin pressures.
ICICI Securities remained constructive on NALCO, Narayana Health and Jupiter Life Line Hospitals after their June-quarter performance, citing long-term growth catalysts despite near-term operational challenges.
ICICI Securities remains constructive on Archean Chemical, GSK Pharma, MakeMyTrip and Nexus Select, citing improving earnings visibility, growth investments, market-share gains and sustained demand trends across sectors.
ICICI Securities noted that Kansai Nerolac reported 9.8% YoY revenue growth in Q1 FY27, its strongest growth performance in the last 13 quarters.
ICICI Securities highlighted opportunities across healthcare, consumer staples, housing finance and REITs, while maintaining a cautious stance on RailTel despite steady execution and a robust order book.
LIC Housing Finance's disbursements increased 14.5% YoY to Rs 15,000 crore, while assets under management growth continued to be subdued at 4% YoY, with FY27 loan growth guidance trimmed to 8-10% vs low double digits guided before, highlights the brokerage.
Despite the ongoing US-Iran conflict blocking the Strait of Hormuz and the stoppage of LNG shipments from Qatar Energy, GAIL saw a recovery in gas transmission volumes and sharply stronger gas trading profitability for Q1, boosting earnings, adds ICICI Securities.
Tata Power's RE capacity addition was muted in Q1 at 226MW; however, it expects a much better Q2 and maintained its guidance of 2.5GW for FY27, adds the brokerage.
The brokerage cited weak execution, slower order-book additions and limited visibility on near-term revenue conversion as reasons for its cautious stance.